Sign up to save your podcasts
Or
Share E49: IL17i vs. TNFi for Psoriatic Arthritis (SPIRIT-H2H)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
E49: IL17i vs. TNFi for Psoriatic Arthritis (SPIRIT-H2H)
Today I dive into the emerging therapies for psoriatic arthritis, focusing on the IL17i ixekizumab and the recently published SPIRIT-H2H trial. It's a great combination of my favorite thing in RCTs (head to head trials) and my least favorite thing in RCTs (RCTs that were designed in such a way that they don't answer the question I want to know).
View all episodes
By Michael Putman
4.9
111111 ratings
Today I dive into the emerging therapies for psoriatic arthritis, focusing on the IL17i ixekizumab and the recently published SPIRIT-H2H trial. It's a great combination of my favorite thing in RCTs (head to head trials) and my least favorite thing in RCTs (RCTs that were designed in such a way that they don't answer the question I want to know).
More shows like The Evidence Based Rheumatology Podcast
View all
JAMA Clinical Reviews
496 Listeners
Rheumnow Podcast
118 Listeners
The Curbsiders Internal Medicine Podcast
3,321 Listeners
Core IM | Internal Medicine Podcast
1,081 Listeners
Healio Rheuminations
119 Listeners
The Clinical Problem Solvers
514 Listeners
ACR on Air
67 Listeners
Around the Rheum
5 Listeners
Rheumatology For The Royal College
171 Listeners
RheumMadness Podcast
11 Listeners
The Lancet Rheumatology in conversation with
0 Listeners
Talking Rheumatology Research
1 Listeners
Talking Rheumatology
0 Listeners
Talking Rheumatology Spotlight
5 Listeners
ACR Journals On Air
18 Listeners